Orchid Pharma Returns to Profit With ₹28.6 Crore Q2 PAT
Key highlights
- Orchid Pharma reported Q2 FY27 consolidated net profit of ₹28.6 crore versus a ₹5.7 crore loss in Q2 FY26.
- Q2 FY27 revenue rose 76.3% year-on-year to ₹341.3 crore and increased 12.2% from Q1 FY27.
- Operating profit improved to ₹24.1 crore and operating margin rose to 7.1% from negative 0.8% a year earlier.
- Half-year operating cash flow was ₹117.8 crore, while consolidated borrowings stood at ₹543.7 crore at September 2026.
powered by IRIS

Orchid Pharma Limited returned to consolidated profitability in Q2 FY27, reporting net profit of ₹28.6 crore against a loss of ₹5.7 crore in Q2 FY26, as revenue rose 76.3% year-on-year to ₹341.3 crore for the quarter ended September 30, 2026.
Know Orchid Pharma inside out
Results, valuation, peers and who's buying, in one view.
What did Orchid Pharma report in Q2 FY27?
Orchid Pharma reported consolidated revenue of ₹341.3 crore in Q2 FY27, compared with ₹193.5 crore in the year-earlier quarter and ₹304.2 crore in Q1 FY27. The quarterly revenue figure represented growth of 76.3% year-on-year and 12.2% sequentially.
The company posted consolidated profit after tax of ₹28.6 crore, compared with a ₹5.7 crore net loss in Q2 FY26. Profit was also substantially higher than ₹3.2 crore in the preceding quarter. Earnings per share were ₹4.77, against a loss per share of ₹1.13 a year earlier and ₹0.54 in Q1 FY27.
The results were approved by Orchid Pharma's board on November 14, 2026. They cover the July to September period and were issued as unaudited financial results, accompanied by statutory auditors' limited review reports.
How did revenue and operating profitability change?
Orchid Pharma's operating profit rose to ₹24.1 crore in Q2 FY27 from an operating loss of ₹1.5 crore in Q2 FY26 and ₹14.0 crore in Q1 FY27. Operating margin improved to 7.1%, compared with negative 0.8% a year earlier and 4.6% in the preceding quarter.
Total expenditure increased 60.0% year-on-year to ₹332.2 crore, below the 76.3% rise in revenue. Materials and purchases were ₹208.0 crore, employee cost was ₹31.4 crore, and other expenses were ₹77.3 crore. Other expenses rose 105.3% from the prior-year quarter and 33.7% from Q1 FY27.
Profit before tax was ₹26.8 crore, against a loss before tax of ₹3.3 crore in Q2 FY26 and profit before tax of ₹2.6 crore in Q1 FY27. Other income stood at ₹17.8 crore, compared with ₹10.8 crore a year earlier and ₹1.8 crore in the prior quarter. This means the quarterly bottom line included a meaningful contribution from other income alongside the improvement in operating profit.
What was the role of the Dhanuka Laboratories amalgamation?
The September quarter was Orchid Pharma's first full quarter after the amalgamation of Dhanuka Laboratories. The company described the period as the first full quarter of merged operations, making year-on-year comparisons subject to the presentation and restatement of comparative figures in its financial disclosures.
The reported revenue increase and return to profit therefore need to be read alongside this change in the corporate structure. The available results data show a sharp increase in consolidated revenue and a move from operating loss to operating profit, but the filing does not provide an earnings-call transcript or management guidance for the quarter.
The company has stated a target operating-margin range of 20% to 22% going forward in its investor presentation. Q2 FY27 operating margin of 7.1% remained below that stated range. Orchid Pharma also referred to efforts to control costs and optimise operations, though the results statement did not set a timetable for achieving the target range.
Got a follow-up? Ask IRIS
What do the balance-sheet and cash-flow figures show?
Orchid Pharma reported half-year operating cash flow of ₹117.8 crore, compared with an outflow of ₹4.7 crore in the corresponding period of the previous year. Cash balance increased to ₹46.6 crore from ₹7.1 crore at the end of March 2026.
Trade receivables declined to ₹348.2 crore from ₹381.4 crore over the same period. The movement in receivables and operating cash flow provides additional context to the reported quarterly profit, particularly for a pharmaceutical manufacturer where working-capital management can affect cash conversion.
The company said proceeds of ₹394.5 crore from its qualified institutional placement had been fully used. Of this, ₹195.5 crore was used for debt repayment or prepayment, while ₹135.0 crore was allocated to the Jammu manufacturing facility.
What should investors monitor after the Q2 FY27 result?
Investors will likely assess whether Orchid Pharma can sustain operating-profit growth while managing expenses and improving its operating margin. Revenue grew faster than total expenditure in the quarter, and operating margin improved by 2.5 percentage points from Q1 FY27, but other income was also a material component of pre-tax profit.
Consolidated borrowings were ₹543.7 crore at September 2026, compared with ₹301.4 crore at March 2026. The increase in borrowings, alongside the use of qualified institutional placement proceeds for debt repayment and the Jammu facility, makes debt levels, financing costs and capital deployment relevant items for subsequent disclosures.
Finance cost was ₹3.6 crore in Q2 FY27, broadly unchanged from ₹3.7 crore in Q2 FY26 but higher than ₹2.2 crore in Q1 FY27. The company has not published an earnings-call transcript for the quarter, so the reported financial statement remains the primary source for assessing the result.
Conclusion
Orchid Pharma's Q2 FY27 result marked a return to consolidated profitability, with ₹28.6 crore of net profit, revenue of ₹341.3 crore and operating margin of 7.1%. The full quarter following the Dhanuka Laboratories amalgamation also showed stronger operating profit and improved cash generation compared with the previous year.
The next key disclosures will indicate whether revenue growth and operating-margin improvement can continue, how the Jammu manufacturing-facility spending progresses, and how consolidated borrowings evolve after reaching ₹543.7 crore at September 2026.


